Multivariate risk assessment and risk score cards in hypertension

Vascular Health and Risk Management

Volumn 3, Issue 3, 2007, Pages 313-320

  Tocci, Giuliano ^a   Valenti, Valentina ^a   Sciarretta, Sebastiamo ^a   Volpe, Massimo ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

Cardiovascular prevention; Global cardiovascular risk; Hypercholesterolemia; Hypertension

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PERINDOPRIL;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERANCE; HEART PROTECTION; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; MORBIDITY; MORTALITY; PATHOGENESIS; PRIMARY MEDICAL CARE; REVIEW; RISK ASSESSMENT; RISK REDUCTION;

BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL; HEALTH BEHAVIOR; HUMANS; HYPERTENSION; MYOCARDIAL ISCHEMIA; RISK ASSESSMENT; RISK FACTORS;

EID: 34547764304     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. [ADA] American Diabetes Association. 2004. Hypertension management in adults with diabetes. Diabetes Care, 27:S65-S67.
2. Anderson KM, Odell PM, Wilson PW, et al. 1991. Cardiovascular disease risk profiles. Am Heart J, 121 (1 Pt 2):293-8.
3. Alderman MH, Furberg CD, Kostis JB, et al. 2002. Hypertension guidelines: criteria that might make them more clinically useful. Am J Hypertens, 15(10 Pt 1):917-23.
4. [ALLHAT] Officers and Coordinators for the ALLHAT Collaborative Research Group. 2002. The Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA, 288:2981-97.
5. Andersson OK, Almgren T, Persson B, et al. 1998. Survival in treated hypertension: follow up study after two decades. Brit Med J, 317:167-71.
6. [BPLTTC] Blood Pressure Lowering Treatment Trialists' Collaboration. 2000. Effect of Angiotensin-converting enzyme inhibitors, calcium antagonists, and other blood pressure lowering drugs: results of prospectively designed overviews of randomized trials. Lancet, 355:1955-1964.
7. Cannon CP, Braunwald E, McCabe CH, et al; for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thromolysis in Myocardial Infarction 22 Investigators (PROVE IT-TIMI 22). 2004. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med, 350:1495-504.
8. Chobanian A, Bakris G, Black H, et al. 2003. The Seventh Report of the Joint National Committee (JNC) on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA, 289:2560-2571.
9. Collins R, Peto R, MacMahon S, et al. 1990. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet, 335:827-839.
10. Conroy RM, Pyorala K, Fitzgerald AP, et al; for the SCORE Project Group. 2003. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J, 24:987-1003.
11. Dahlof B, Devereux RB, Kjeldsen SE, et al; for the LIFE Study Group. 2002. Cardiovascular morbidity and mortality in the Losartan Intervention For End-point reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 359:995-1003.
12. Dahlof B, Sever PS, Poulter NR, et al; for the ASCOT Investigators. 2005. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, la the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet, 366(9489):895-906.
13. [ESH/ESC] European Society of Hypertension/European Society of Cardiology. 2003. European Society of Hypertension (ESH)/European Society of Cardiology (ESC) guidelines for the management of arterial hypertension. J Hypertens, 21:1011-1053.
14. Gaede P, Vedel P, Larsen N, et al. 2003. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med, 348:383-93.
15. Grundy SM, Balady GJ, Criqui MH, et al. 1998. Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association. Circulation, 97:1876-87.
16. Grundy SM, Pasternak R, Greenland P, et al. 1999. Assessment of Cardiovascular Risk by use of multiple-risk-factor assessment equations. A Statement for Healthcare Professional from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol, 34:1348-59.
17. Hansson L, Zanchetti A, Carruthers SG, et al; for the HOT Study Group. 1998. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet, 351:1755-1762.
18. Haq IU, Ramsay LE, Yeo WW, et al. 1999. Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high-risk men. Heart, 81:40-6.
19. [HDFPCG] Hypertension Detection and Follow-up Program Cooperative Group. 1979. Five-year findings of the hypertension detection and follow-up program. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group. JAMA, 242:2562-71.
20. [HPS] Heart Protection Study Collaborative Group. 2002. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 360:7-22.
21. Julius S, Kjeldsen SE, Weber M, et al; for the VALUE Trial Group. 2004. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) randomised trial. Lancet, 363:2022-31.
22. Kannel WB. 2000. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens, 13(1 Pt 2):3S-10S.
23. LaRosa JC, Grundy SM, Waters DP, et al; for the Treating to New Targets (TNT) Investigators. 2005. Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease. N Engl J Med, 352:1425-35.
24. Lewington S, Clarke R, Qizilbash N, et al; for the Prospective Studies Collaboration. 2002. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet, 360:1903-13.
25. Libby P. 2005. The forgotten majority. Unfinished business in cardiovascular risk reduction. J Am Coll Cardiol, 46:1225-8.
26. MacMahon S, Peto R, Cutler J, et al. 1990. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet, 335:765-774.
27. Mancia G, Sega R, Milanesi C, et al. 1997. Blood pressure control in the hypertensive population. Lancet, 349:454-7.
28. Menotti A, Puddu PE, Lanti M. 2000. Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study. Eur Heart J, 21:365-70.
29. [NCEP] National Cholesterol Education Program. 2002. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report. Circulation, 106:3143-3421.
30. Ruilope LM, Rosei EA, Bakris GL, et al. 2005. Angiotensin receptor blockers: therapeutic targets and cardiovascular protection. Blood Press, 14(4):196-209.
31. Sever PS, Dahlof B, Poulter NR, et al. 2003. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet, 361:1149-58.
32. Stamler J, Wentworth D, Neaton JD. 1986. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356.222 primary screeners of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA, 256:2823-2828.
33. [PROGRESS] The Perindopril pROtection aGainst REcurrent Stroke Study Collaborative Group. 2001. Randomized trial of perindopril-based bloodpressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet, 358:1033-1041.
34. Thomsen TF, McGee D, Davidsen M, et al. 2002. A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study. Int J Epidemiol, 31:817-22.
35. [UKPDS] United Kingdom Prospective Diabetes Study Group. 1998. Tight Blood Pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS38. Brit Med J, 317:703-713.
36. Van den Hoogen PC, Feskens EJ, Nagelkerke NJ, et al. 2000. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. N Engl J Med, 342:1-8.
37. Vasan RS, Larson MG, Leip EP, et al. 2001. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med, 345(18):1291-7.
38. Volpe M, Alderman MH, Furberg CD, et al. 2004. Beyond hypertension toward guidelines for cardiovascular risk reduction. Am J Hypertens, 17(11 Pt I):1068-74.
39. Volpe M, Ruilope LM, McInnes GT, et al. 2005. Angiotensin-II receptor blockers: benefits beyond blood pressure reduction? J Hum Hypertens, 19:331-9.
40. Wolf-Maier K, Cooper RS, Banegas JR, et al. 2003. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA, 289:2363-9.
41. [WHO/ISH] World Health Organization/International Society of Hypertension. 2003. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens, 21:1983-1992.
42. Yusuf S, Hawken S, Ounpuu S, et al. 2004. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet, 364:937-52.
43. Yusuf S, Sleight P, Dagenais G, et al. for the Hearth Outcomes Prevention Evaluation (HOPE) Study Group. 2002. Effects of angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med, 342:145-53.